Two new GSK oral oncology treatments, BRAF-inhibitor TafinlarA ...

GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration has approved both TAFINLAR and MEKINIST .

http://www.freshnews.com/news/804713/two-new-gsk-oral-oncology-treatments-braf-inhibitor-tafinlar-dabrafenib-capsules-and-fi